Community Bank of Raymore Has $1.19 Million Holdings in Pfizer Inc. $PFE

Community Bank of Raymore increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 20.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,130 shares of the biopharmaceutical company’s stock after acquiring an additional 8,500 shares during the period. Community Bank of Raymore’s holdings in Pfizer were worth $1,191,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares in the last quarter. Northern Trust Corp lifted its position in shares of Pfizer by 6.8% during the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after purchasing an additional 3,943,397 shares in the last quarter. Amundi grew its stake in shares of Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock valued at $767,709,000 after purchasing an additional 838,198 shares in the last quarter. Finally, Deutsche Bank AG raised its position in Pfizer by 7.0% in the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company’s stock worth $715,581,000 after purchasing an additional 1,846,436 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PFE. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Morgan Stanley decreased their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Bank of America boosted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.13.

Pfizer Trading Up 1.2%

NYSE PFE opened at $24.52 on Monday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.36. The stock has a 50-day simple moving average of $24.89 and a 200 day simple moving average of $24.11. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $139.38 billion, a PE ratio of 13.04, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.